Anti-PDLIM7 Polyclonal Antibody from ProteoGenix; catalogue ARO-A22061; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Introducing our Anti-PDLIM7 Polyclonal Antibody – the perfect tool for your biotech research needs. This highly specific and sensitive antibody targets PDLIM7, a protein involved in various cellular processes and signaling pathways. With its exceptional performance and versatility, our Anti-PDLIM7 Polyclonal Antibody is a valuable addition to any laboratory.
PDLIM7, also known as Enigma homolog protein, is a member of the PDZ-LIM protein family. It plays a crucial role in regulating cell signaling, cytoskeletal organization, and gene expression. PDLIM7 has been linked to various diseases, including cancer, cardiovascular disorders, and neurological disorders. Our Anti-PDLIM7 Polyclonal Antibody binds to PDLIM7 with high affinity, making it an ideal tool for studying its function and role in disease development.
Our Anti-PDLIM7 Polyclonal Antibody is suitable for various applications, including Western blotting, immunohistochemistry, and immunofluorescence. It has been validated for use in multiple species, including human, mouse, and rat. This makes it a versatile choice for researchers working with different model systems.
This antibody has been extensively tested in various experimental settings, and has shown excellent performance in detecting PDLIM7 in different cell and tissue types. In Western blot analysis, it has been shown to specifically recognize PDLIM7 at its expected molecular weight. In immunofluorescence, it displays strong and specific staining of PDLIM7 in both fixed and live cells. Furthermore, in immunohistochemistry, it has been successfully used to visualize PDLIM7 in tissue sections.
With its high specificity and sensitivity, our Anti-PDLIM7 Polyclonal Antibody is a valuable tool for studying PDLIM7 in different research areas, including cancer biology, cardiovascular research, and neurobiology. It can also aid in the development of potential therapeutics targeting PDLIM7.
In conclusion, our Anti-PDLIM7 Polyclonal Antibody is a reliable and efficient reagent for your biotech research needs. Its exceptional performance, versatility, and validated applications make it a top choice for scientists studying PDLIM7. Order now and take your research to the next level!
ProteoGenix catalogue number ARO-A22061. For research use only.
Target: PDZ and LIM domain protein 7; LIM mineralization protein; LMP; Protein enigma; PDLIM7; ENIGMA; Clonality: Polyclonal Antibody; Applications: IHC, ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA | IHC |
|---|---|---|---|---|---|---|---|---|---|
| PDZ and LIM domain protein 7; LIM mineralization protein; LMP; Protein enigma; PDLIM7; ENIGMA |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
